Artículos relacionados
Área salud
Characteristics, Treatment, and Safety Profile of Patients With Atopic Dermatitis According to Eligibility for Randomized Clinical Trials: An Analysis From the Spanish Atopic Dermatitis Registry (BIOBADATOP)
marzo 26, 2026
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 117. Núm. 1. (Enero 2026)
Background Randomized clinical trials (RCTs) supporting advanced treatments for atopic dermatitis (AD) involve highly selected patients, limiting their generalizability. Objective To determine the proportion of adults on advanced systemic therapy for AD in clinical practice […]
Área salud
FR – Nuevos tratamientos en lupus eritematoso cutáneo: presente y futuro
septiembre 16, 2025
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 116. Núm. 8. (septiembre 2025)
Área salud
Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses
enero 15, 2025
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 116. Núm. 1. (enero 2025)
Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous […]
